Loading…
Fredun Pharmaceuticals (FREDUN)₹1,519−0.13%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Fredun Pharmaceuticals reported sales of ₹229 Cr, up 89.9% from Jun 2025, and net profit of ₹13.02 Cr, up 85.7% year on year. For the year to Mar 2026, sales were ₹637 Cr and net profit ₹33.02 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|
| Sales | 168 | 120 | 145 | 162 | 214 | 229 |
| Expenses | 150 | 103 | 123 | 135 | 184 | 196 |
| Operating Profit | 16.99 | 16.98 | 21.99 | 25.99 | 28.96 | 32.96 |
| OPM % | 10.0% | 14.0% | 15.0% | 16.0% | 14.0% | 14.0% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 8.01 | 7.01 | 8.01 | 11.01 | 14.02 | 9.01 |
| Depreciation | 1.99 | 0.99 | 1.99 | 1.99 | 2.99 | 3.99 |
| Profit before tax | 6.98 | 8.97 | 12.96 | 13.95 | 10.97 | 20.92 |
| Tax % | 17.0% | 25.0% | 26.0% | 25.0% | 4.0% | 36.0% |
| Net Profit | 6.01 | 7.01 | 9.01 | 10.01 | 11.01 | 13.02 |
| EPS (Rs) | 4.22 | 4.76 | 6.63 | 6.50 | 6.56 | 7.95 |
| Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|
| Sales | 455 | 637 | 750 |
| Expenses | 401 | 545 | 638 |
| Operating Profit | 51.96 | 90.87 | 110 |
| OPM % | 12.0% | 14.0% | 14.7% |
| Other Income | 1.99 | 3.99 | 0.00 |
| Interest | 22.01 | 39.05 | 42.05 |
| Depreciation | 4.99 | 7.98 | 10.96 |
| Profit before tax | 26.92 | 46.86 | 58.80 |
| Tax % | 28.0% | 31.0% | — |
| Net Profit | 20.02 | 33.02 | 43.05 |
| EPS (Rs) | 13.88 | 19.86 | 27.64 |
| Dividend payout % | 2.0% | 1.0% | — |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 5.01 | 5.01 |
| Reserves | 137 | 274 |
| Borrowings | 167 | 223 |
| Other Liabilities | 180 | 143 |
| Total Liabilities | 489 | 644 |
| Fixed Assets | 52.88 | 118 |
| CWIP | 0.00 | 0.00 |
| Investments | 1.99 | 1.99 |
| Other Assets | 435 | 524 |
| Inventories | 240 | 270 |
| Trade receivables | 177 | 93.19 |
| Cash & equivalents | 4.99 | 65.04 |
| Total Assets | 489 | 644 |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Cash from operating activity | −17.05 | 12.03 |
| Cash from investing activity | −6.02 | −74.24 |
| Cash from financing activity | 26.99 | 121 |
| Net cash flow | 4.01 | 60.03 |
| Capex | 6.01 | 73.99 |
| Free cash flow | −22.95 | −61.86 |
| CFO / OP % | −31.9% | 13.0% |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor days | 142 | 53 |
| Inventory days | 267 | 219 |
| Days payable | 161 | 71 |
| Cash conversion cycle | 247 | 200 |
| Working capital days | 75 | 77 |
| ROCE % | — | 21.1% |
For the Jun 2026 quarter, Fredun Pharmaceuticals reported sales of ₹229 Cr, up 89.9% year on year and net profit of ₹13.02 Cr, up 85.7% year on year. The operating margin was 14.0%.
Fredun Pharmaceuticals' sales for the year to Mar 2026 were ₹637 Cr; over the last twelve months they were ₹750 Cr.
Net profit for the year to Mar 2026 was ₹33.02 Cr, and ₹43.05 Cr over the last twelve months. Earnings per share over the same trailing period were ₹27.64.
Fredun Pharmaceuticals reported borrowings of ₹223 Cr at Mar 2026, against cash and equivalents of ₹65.04 Cr.
Cash from operations was ₹12.03 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹61.86 Cr.